The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes

One of the new approaches to the management of type 2 diabetes mellitus (T2DM) consists of orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitors. These synthetic drug inhibitors are reported to have some side effects and that subsequently limits their applications. There is a growing inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Jao, Chia-Ling, Hung, Chuan-Chuan, Tung, Yu-Shan, Lin, Pei-Yi, Chen, Meng-Chun, Hsu, Kuo-Chiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: China Medical University 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534476/
https://www.ncbi.nlm.nih.gov/pubmed/26267061
http://dx.doi.org/10.7603/s40681-015-0014-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534476/
https://www.ncbi.nlm.nih.gov/pubmed/26267061
http://dx.doi.org/10.7603/s40681-015-0014-9

Ejemplares similares